Evidence map›Paper›PMID 38492198›Full record

Observational studyInternational journal of hematology2024

Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study.

Jun Takizawa, Ritsuro Suzuki, Koji Izutsu, Toru Kiguchi, Hideki Asaoku, Yoshio Saburi, Taro Masunari, Atae Utsunomiya, Kengo Takeuchi, Naoya Nakamura and 5 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 2 countries.

Jun TakizawaDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan. juntaki@med.niigata-u.ac.jp.ORCID http://orcid.org/0009-0000-7125-3927
Ritsuro SuzukiShimane University Hospital, Cancer Center, Izumo, Japan.
Koji IzutsuDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Toru KiguchiDepartment of Hematology, Chugoku Central Hospital, Fukuyama, Japan.
Hideki AsaokuDepartment of Hematology, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Yoshio SaburiDepartment of Hematology, Oita Prefectural Hospital, Oita, Japan.
Taro MasunariDepartment of Hematology, Chugoku Central Hospital, Fukuyama, Japan.
Atae UtsunomiyaDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.
Kengo TakeuchiPathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Naoya NakamuraDepartment of Pathology, Tokai University, Isehara, Japan.
Koichi OhshimaDepartment of Pathology, Kurume University, Kurume, Japan.
Michaela GruberDepartment of Internal Medicine 1, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Ulrich JägerDepartment of Internal Medicine 1, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Sadao AokiPathophysiology, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.
Junji SuzumiyaShimane University Hospital, Cancer Center, Izumo, Japan.
Chugoku Central Hospital · JPMedical University of Vienna · ATHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPImamura Hospital · JPJapanese Foundation For Cancer Research · JPKoga Hospital · JPKurume University · JPNiigata University · JPNiigata University of Pharmacy and Medical and Life Sciences · JPOita Prefectural Hospital · JPShimane University · JPTokai University · JPTokyo National Hospital · JP

Funding

Japan Society for the Promotion of Science 16K08963Japan Society for the Promotion of Science 19K07863Japan Society for the Promotion of Science 23K06848
6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is rare in Japan. We conducted the nationwide, prospective observational study CLLRSG-01 to clarify the current state of CLL in Japan and to make accurate international comparisons by preparing naturally air-dried smears like those used in other countries. Of the 201 untreated patients enrolled and evaluated, 119 were diagnosed with CLL and 82 with non-CLL mature B-cell neoplasms, based on the WHO classification. Of the 119 CLL patients, 90 were classified as typical and 29 as atypical according to FAB classification morphology, with the proportion of atypical CLL consistent with reports from other countries. Immunophenotypic analyses by flow cytometry showed that 55% of Japanese CLL patients had a Matutes score of 4 or higher, which is lower than the rate of about 90% in Europeans. Mutated IGHV was identified in 80% of Japanese CLL patients, which is a higher rate than in Western patients. The most frequent IGHV gene was VH3-30 (15%), followed by VH3-23 (12%) and VH4-34 (10%). VH1-69, the most common gene in Western countries, was identified in only one patient. These results indicate that the pattern of immunophenotypes and IGHV gene usage in Japanese CLL patients differs from that in Western patients.

Indexed as

ImmunophenotypingLeukemia, Lymphocytic, Chronic, B-CellAdultAgedAged, 80 and overFemaleHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionJapanMaleMiddle AgedMutationProspective StudiesImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionCharacteristics of Japanese CLLCLLCLLRSG-01IGHV gene usageMutated IGHV

Identifiers

PMID38492198
OpenAlexW4392881697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.